Results of treatment of patients with stage I uterine sarcoma
Davydiuk S.S., Kryzhanivska A.Y.
Summary. The goal. To analyze the results of treatment of patients with stage I uterine sarcoma. Object and research methods. The analysis of the results of the treatment of 83 women with uterine sarcoma (US) stage I p(T1N0M0) who underwent surgical intervention from 2010 to 2023 in the conditions of the Municipal Non-Profit Institution «Precarpathian Clinical Oncology Center of the Ivano-Frankivsk Regional Council» and the National Cancer Institute of the Ministry of Health of Ukraine was carried out. The criteria for the effectiveness of treatment were the rates of recurrence-free survival of patients during the entire observation period and the frequency of tumor recurrence and metastasis. The follow-up period ranged from 1.0 to 156.0 months. The results. of the study for patients with US were evaluated by classifying patients according to the main prognostic factors: age, stage and histology of the tumor. In our study, we divided the patients into two groups, those who received adjuvant therapy and those who received no adjuvant. Retrospective analysis of overall and recurrence-free survival was performed. Main results. The average age of the analyzed patients: among patients with US I p(T1N0M0) stage, the age ranged from 31 to 88 years. All patients were divided into two groups, depending on whether they received further treatment after surgery. The first group consisted of 45 patients with stage I SM who did not receive adjuvant therapy and started treatment from 2010 to 2023 inclusive (group 1). The effectiveness of the treatment of all patients was monitored retrospectively. The average age of group 1 was 50.4±2.2. According to the histological type of tumor in this study for group I, leiomyosarcoma (LMS) is 40 people (88.9%), and endometrial stromal sarcoma (ESS), only 5 people (11.1%). The second group consisted of 38 patients with US stage I who received adjuvant therapy. The average age of this group of patients was 56.2±1.6. The age of this group of patients varied from 36 to 73 years. According to the histological type of the tumor in this study for the II group, LMS is 26 people (68.4%), and ESS? only 12 people (31.6%).Rates of recurrence-free survival during 60 months of follow-up are significantly higher in the first group of patients who did not receive adjuvant treatment for stage I US, compared to the second follow-up group. The overall survival rates during the 60-month follow-up are higher in the I group of patients who did not receive adjuvant treatment for stage I US, compared to the II group of patients. Conclusions. The peak incidence fell on the age group of 40–59 years — 57.8%, patients with US I–II groups. The most common histological type for groups I–II is LMS. According to the degree of tumor differentiation (G), for group I (patients of stage I who did not receive adjuvant therapy), LMS G1 prevails, for group II (patients of stage I who received adjuvant therapy), LMS G2 prevails. Most of the patients for the I–II groups had an unencumbered oncology history. Most of the patients had a history of uterine leiomyoma. The 1st group of patients with LM in the anamnesis — 53.3%, the 2nd group of patients with LM in the anamnesis — 65.8%. Higher rates of recurrence-free and overall survival for patients with stage I US who did not receive adjuvant treatment — Group I.
Leave a comment